Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

l mode of action, including its magnetic resonance imaging detectability, provides the opportunity for Xcytrin to be used in a broad range of cancers. In previously conducted randomized trials, Xcytrin combined with whole brain radiation therapy (WBRT) has been shown to prolong time to neurologic progression in patients with brain metastases from NSCLC. Xcytrin's non-overlapping toxicity makes it an appealing agent to use in combination with standard chemotherapy regimens.

The target for Xcytrin is the enzyme thioredoxin reductase, which is frequently overexpressed in lung cancer cells. This enzyme has been shown to confer to cancer cells characteristics of aggressive tumor growth and resistance to chemotherapy. First-line therapy for advanced NSCLC includes combination chemotherapy using drugs such as carboplatin, cisplatin, Gemzar(R), taxanes and others. Currently approved agents for second-line treatment of NSCLC include Alimta, Tarceva(R) and Taxotere.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. A New Drug Application for use of Xcytrin in combination with WBRT for treatment of brain metastases from NSCLC was filed with the Food and Drug Administration in April 2007. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. In addition, more information about advocacy on behalf of Xcytrin can be found at




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/25/2014)... 25, 2014  Semler Scientific, Inc. (Nasdaq: ... assessment company that develops patented products that assist ... diseases, today reported financial results for the second ... "The second quarter of 2014 ... Doug Murphy-Chutorian , M.D., chief executive officer of ...
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... PARK, Kan. , July 24, 2014 /PRNewswire/ ... of two compounds that will be added to ... with Australian-based CIMTECH Pty Ltd, a biotechnology company. ... PAR 122 have shown promise in bone regeneration ... license to develop the compounds for the veterinary ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
... , May 20 As the medical device industry gathers ... of Sales Content Management software, offers medical device companies a solution to ... , , ... Sciences at Prolifiq, will lead the workshop "Sales-Friendly Compliant Content Communication: How ...
... NEW YORK , May 19 ... stage, specialty pharmaceutical and medical device company focused on ... Oncology (ASCO) has accepted an oral presentation of Delcath,s ... (PHP-mel) to the best alternative care for patients with hepatic ...
Cached Medicine Technology:Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment 2Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment 3Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago 2Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago 3
(Date:7/25/2014)... 25, 2014 As reported by the New ... Marijuana Increasing (7/3), the state of Louisiana has recently ... so even than cocaine. Officials believe the increase is due ... a “form” of marijuana. However, both doctors and police confirm ... far as to call it “poison,” doctors have acknowledged that ...
(Date:7/25/2014)... Consuming too much salt? Overloaded on fats, sugars ... labels! , Learn to decipher the valuable information on ... during a "Healthy Eating for You: Label Reading" presentation ... Ohltown Road, Austintown. , Registered dietician and community educator ... questions. , The presentation is free and open ...
(Date:7/25/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... Heather M. Young, PhD, RN, FAAN, of the ... of the Doris Schwartz Gerontological Nursing Research Award. ... Sciences Section, is given to a member of ... contribution to gerontological nursing research. , The award ...
(Date:7/25/2014)... USA (PRWEB) July 25, 2014 As reported ... Use, OD Deaths Increase (7/20), Michigan has seen a nearly ... four years. While the count was 271 between 1999 and ... range. DEA Agents believe that, like other states, drug users ... the drug via prescription pills. He compared the price of ...
(Date:7/25/2014)... As reported by People Magazine in the article ... Getting Sober (7/15), one of the most popular cast ... to the public about his personal transformation. Now, two years ... that moving on with his life was a challenge. He ... in 2012 and even spent some time in rehab. He ...
Breaking Medicine News(10 mins):Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Learn to Decipher Food Labels at Humility House 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3
... of AED Improves Survival Rates. , ... Rosemont, IL (Vocus) December 30, ... comprehensive emergency action plan (EAP) at an athletic event can mean the ... Cardiac Arrest (SCA) , confirms a study published in the inaugural edition ...
... registered its one-millionth member just 14 months after its launch last ... a more active role in managing their own healthcare. ... ... -- Helping Patients and Physicians , , , "Despite enormous ...
... American Scientific Resources, Inc. (Pink Sheets: ASFX), today announced the ... directors: Mr. Felix Reznick and Ms. Teresa McWilliams, American ... Boston College Law School and the New York ... Boston College Law School (J.D. 1998), and was ...
... 30 Delcath Systems, Inc. (Nasdaq: DCTH ... quarterly update conference call at 4:30 PM Eastern Time ... Chief Executive Officer of Delcath Systems, will host the ... patient enrollment and the advancement of clinical studies. ...
... can revitalize a company or a sports team. Recent research ... body good as well, especially when it comes to fighting ... from the Department of Psychology,s Neuroimmunology Research Unit, discovered that ... stored for less than 9 days increased the odds ...
... Jr., chairman and chief executive officer, Medco Health Solutions, Inc. ... Goldman Sachs Healthcare CEOs Unscripted: A View from the Top ... presentation will begin at 11:15 a.m. EST and Richard J. ... Additionally, Snow will participate on a CEO panel, "Tackling the ...
Cached Medicine News:Health News:Study Stresses Importance of Availability of Automated External Defibrillators at Athletic Events 2Health News:Study Stresses Importance of Availability of Automated External Defibrillators at Athletic Events 3Health News: One Million Americans Now Receive Personalized FDA Drug Safety Alerts Through iGuard.org 2Health News: One Million Americans Now Receive Personalized FDA Drug Safety Alerts Through iGuard.org 3Health News:American Scientific Resources Announces Addition of New Board Members 2Health News:Delcath Systems to Host Quarterly Update Conference Call 2Health News:Delcath Systems to Host Quarterly Update Conference Call 3Health News:Young blood fights cancer 2Health News:Young blood fights cancer 3Health News:Medco CEO to Present at the 2009 Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Conference 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: